Eli Lilly and Company– tag –
-
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 2026
PrivateDoc® Unknown Overview By 2026, two oral GLP-1 receptor agonists, Foundayo (orforglipron) and Wegovy pill (oral semaglutide), are approved for weight management in the UK. Foundayo, a small-molecule non-peptide, can be taken with o... -
Eli Lilly’s Foundayo® (Orforglipron) Receives FDA Approval as First Oral Non-Peptide GLP-1 Receptor Agonist, Demonstrates Significant Weight Loss and Cardiometabolic Improvement
Obesity Medicine Review Unknown Overview Eli Lilly's Orforglipron, branded as Foundayo®, has received FDA approval as the latest oral GLP-1 receptor agonist. Distinguishing itself from oral semaglutide (Wegovy®) as a small-molecule, non-... -
Eli Lilly’s Oral GLP-1 Agonist Orforglipron Shows Promising Weight Loss and Safety in Phase 2 Trials, Rivaling Injectables
Endocrinology Today USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, demonstrated weight loss comparable to some injectable GLP-1s in Phase 2 trials for obesity and type 2 diabetes. As a non-peptide sma... -
Isomorphic Labs and Recursion Pharmaceuticals Forge Major AI Drug Discovery Alliances with Pharma Giants
flcube.com International Overview Isomorphic Labs, an Alphabet subsidiary, has secured significant AI-driven drug discovery partnerships with Eli Lilly and Novartis to identify novel small molecule therapeutics for undisclosed targets. C... -
Structure Therapeutics’ Oral GLP-1 Aleniglipron Achieves 16.3% Weight Reduction in Phase 2, Advances to Phase 3 Amidst Robust Obesity Pipeline
Becker's Hospital Review Unknown Overview A pipeline update on 13 experimental weight-loss drugs highlights Structure Therapeutics' oral GLP-1 agent, Aleniglipron, which demonstrated a remarkable 16.3% placebo-adjusted weight reduction i... -
Viking Therapeutics Initiates Phase 2 VENTURE-Oral Trial for Oral Dual GLP-1/GIP Agonist VK2735 in Obesity
Superpower USA Overview Viking Therapeutics has commenced its Phase 2 VENTURE-Oral trial in early 2025 for VK2735, an oral dual GLP-1/GIP receptor agonist targeting obesity. This move highlights the intense competition in the metabolic d... -
Eli Lilly’s Oral GLP-1 Agonist ‘Foundayo (orforglipron)’ Receives FDA Approval for Obesity and Overweight Treatment
Drugs.com USA Overview Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, has received FDA approval for adults with obesity or certain weight-related conditions. This small-molecule, non-peptide GLP-1 receptor... -
Eli Lilly Builds Pharmaceutical Industry’s Largest AI Factory with NVIDIA Blackwell DGX SuperPODs, Secures Multi-Billion Dollar Deals with Insilico Medicine and Isomorphic Labs
GlobeNewswire USA Overview In Q2 2026, as AI technology investment accelerated across industries, Eli Lilly announced the construction of the pharmaceutical sector's largest AI factory, powered by NVIDIA Blackwell-based DGX SuperPODs. Co... -
Samsung Biologics Expands to 845,000L Capacity with GSK Facility Acquisition; Lonza, Resilience Announce Major Investments Amidst CDMO Restructuring
DCAT Value Chain Insights USA, South Korea, Switzerland Overview The CDMO industry is undergoing unprecedented restructuring in 2026, driven by major strategic investments and M&A activities by leading players. Samsung Biologics acqu...
